Asa Ren is a leading DNA data company based in Indonesia offering a direct-to-consumer DNA test that delivers more than 360 reports, including predisposed health risks and ancestry. The company performs all analysis in-house to ensure data privacy and provides wellness, nutrition, and clinical bioinformatics data for Indonesians. Its platform links genetic profiles, 360 phenotypes, and medical records to power personalized healthcare and support pharmaceutical research and development. Asa Ren has signed service agreements with more than 47 hospitals and clinics and expects to expand to over 60 partners by the end of 2023. Using new capital it plans to deepen digital capabilities, develop clinical bioinformatics and an electronic health passport, build a clinico-genomic database focused on non-communicable diseases, and add medical diagnosis and complete health data. The company aims to accelerate drug discovery and personalized treatments across disease areas including oncology and cardiovascular disease by leveraging longitudinal and genomic data.

Total raised

$8M

Funding rounds

1

Latest round

Equity

Latest activity

Feb 2023